+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cluster Headache Market by Treatment Type (Nonpharmaceutical, Pharmaceutical), Drug Class (Anti-CGRP Monoclonal Antibodies, NSAIDs, Oxygen Therapy), Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast 2025-2030- Product Image
Cluster Headache Market by Treatment Type (Nonpharmaceutical, Pharmaceutical), Drug Class (Anti-CGRP Monoclonal Antibodies, NSAIDs, Oxygen Therapy), Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast 2025-2030- Product Image
Sale

Cluster Headache Market by Treatment Type (Nonpharmaceutical, Pharmaceutical), Drug Class (Anti-CGRP Monoclonal Antibodies, NSAIDs, Oxygen Therapy), Route Of Administration, End User, Distribution Channel, Payer Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968098
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives seeking data-driven insight into underserved neurological markets will find that the cluster headache market presents new possibilities—and complex challenges—shaped by advances in therapy and shifts in global healthcare policy. This report is designed to enable strategic clarity, providing actionable intelligence for those poised to lead in this high-need segment.

Market Snapshot: Growth Trajectory and Opportunity Overview

The Cluster Headache Market grew from USD 401.80 million in 2024 to USD 425.19 million in 2025. It is expected to continue growing at a CAGR of 5.77%, reaching USD 562.70 million by 2030. The market demonstrates strong potential, underpinned by heightened recognition among specialists, evolving treatment protocols, and innovative device launches. Stakeholders are responding to significant unmet clinical need, driving value for pharmaceutical companies, device manufacturers, and healthcare providers as they compete to shape the next generation of cluster headache solutions.

Scope & Segmentation: Defining Critical Patient Groups, Modalities, and Regions

This comprehensive research delivers a fine-grained analysis of the cluster headache market, focusing on:

  • Treatment Types: Pharmaceutical (Anti-CGRP monoclonal antibodies such as erenumab, fremanezumab, galcanezumab; NSAIDs; triptans—rizatriptan, sumatriptan, zolmitriptan) and nonpharmaceutical interventions (neuromodulation, behavioral therapy, oxygen therapy, including both portable and stationary delivery systems and inhalation models).
  • Drug Classes: Anti-CGRP treatments, NSAIDs, triptans, and oxygen therapy (ragging from inhalation to device-based administration).
  • Route of Administration: Inhalation, nasal, oral, and subcutaneous, with patient-centric differentiation based on speed, convenience, and therapy type.
  • End User Settings: Home care, hospital environments (emergency and neurology departments), as well as specialty clinics and headache centers.
  • Distribution Channels: Hospital pharmacies, online and retail pharmacies, and specialty pharmacy providers.
  • Payer Types: Government reimbursement, private insurance, and out-of-pocket payments illustrating the variety in market access and funding mechanisms.
  • Regions: Americas (U.S., Canada, key South American countries), Europe, Middle East & Africa (major EU nations and select regional growth markets such as Saudi Arabia and South Africa), and Asia-Pacific (including China, India, Japan, Australia, Southeast Asia).
  • Key Innovators: Established global pharmaceutical and device manufacturers like Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and specialty players in both device and digital health segments.

Key Takeaways for Senior Decision-Makers

  • Cluster headache’s clinical complexity and intensity continue to drive urgent demand for specialized management, elevating the need for differentiated acute and preventive strategies.
  • Recent therapeutic innovation is shifting the paradigm toward preventive care, with anti-CGRP agents and neuromodulation devices gaining ground alongside standard abortive regimens.
  • Increased use of personalized medicine, genetic profiling, and biomarker-driven approaches is enabling more targeted therapy selection and earlier intervention for improved outcomes.
  • Market competition is intensifying as leading pharmaceutical firms and device manufacturers invest in R&D, collaborate with tech companies, and pursue regulatory designations to accelerate commercialization.
  • Access to therapy is influenced by reimbursement policies, distribution channel development, and actionable patient support programs, creating a complex environment for market entry and expansion.

Tariff Impact: Navigating U.S. Policy Changes in 2025

Newly imposed United States tariffs on imported medical devices and pharmaceutical ingredients are elevating production costs for cluster headache therapies. Manufacturers are adjusting their strategies by renegotiating supplier contracts, exploring domestic alternatives, and adopting cost-containment measures. The resulting supply chain shifts are influencing payer models and hospital formularies, with transparent negotiations becoming central to maintaining treatment accessibility. Effective management of these tariff-driven disruptions is critical for stakeholder agility and continued patient access.

Methodology & Data Sources

The report leverages a dual approach, combining quantitative data from published clinical research and industry reports with primary insights from interviews with neurologists, reimbursement experts, and industry leaders. This integrated methodology ensures input from both empirical evidence and frontline perspectives, delivering credible, multidimensional intelligence.

Why This Report Matters

  • Empowers executives to anticipate market evolution by offering a holistic understanding of shifts in therapeutic technology and healthcare policy.
  • Supports more informed investment, development, and commercialization strategies with in-depth segmentation and regional profiling.

Conclusion

This analysis provides actionable context for innovation, supply chain adaptation, and market targeting in a complex but promising healthcare segment. Senior leaders can leverage these insights to inform strategy, optimize resource allocation, and prepare for future developments in cluster headache treatment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of CGRP-targeting monoclonal antibodies for preventive therapy in chronic cluster headache patients
5.2. Emergence of neuromodulation devices offering non-pharmacological treatment options for refractory cluster headaches
5.3. Development of high-concentration intranasal treatments delivering rapid relief during acute cluster headache attacks
5.4. Rising investment in digital health platforms enabling remote monitoring and telemedicine for cluster headache management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cluster Headache Market, by Treatment Type
8.1. Introduction
8.2. Nonpharmaceutical
8.2.1. Behavioral Therapy
8.2.2. Neuromodulation
8.2.3. Oxygen Therapy
8.2.3.1. Delivery Systems
8.2.3.1.1. Portable
8.2.3.1.2. Stationary
8.2.3.2. Inhalation
8.3. Pharmaceutical
8.3.1. Anti-CGRP Monoclonal Antibodies
8.3.1.1. Erenumab
8.3.1.2. Fremanezumab
8.3.1.3. Galcanezumab
8.3.2. NSAIDs
8.3.3. Triptans
8.3.3.1. Rizatriptan
8.3.3.2. Sumatriptan
8.3.3.3. Zolmitriptan
9. Cluster Headache Market, by Drug Class
9.1. Introduction
9.2. Anti-CGRP Monoclonal Antibodies
9.2.1. Erenumab
9.2.2. Fremanezumab
9.2.3. Galcanezumab
9.3. NSAIDs
9.4. Oxygen Therapy
9.4.1. Delivery Systems
9.4.1.1. Portable
9.4.1.2. Stationary
9.4.2. Inhalation
9.5. Triptans
9.5.1. Rizatriptan
9.5.2. Sumatriptan
9.5.3. Zolmitriptan
10. Cluster Headache Market, by Route Of Administration
10.1. Introduction
10.2. Inhalation
10.3. Nasal
10.4. Oral
10.5. Subcutaneous
11. Cluster Headache Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospital
11.3.1. Emergency Department
11.3.2. Neurology Department
11.4. Specialty Clinics
11.4.1. Headache Centers
11.4.2. Neurology Clinics
12. Cluster Headache Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Pharmacies
13. Cluster Headache Market, by Payer Type
13.1. Introduction
13.2. Government Reimbursement
13.3. Out-Of-Pocket
13.4. Private Insurance
14. Americas Cluster Headache Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cluster Headache Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cluster Headache Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Eli Lilly and Company
17.3.2. H. Lundbeck A/S
17.3.3. Viatris Inc.
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.5. AbbVie Inc.
17.3.6. Amgen Inc.
17.3.7. Novartis AG
17.3.8. Pfizer Inc.
17.3.9. Almirall S.A.
17.3.10. GlaxoSmithKline plc
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. CLUSTER HEADACHE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CLUSTER HEADACHE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CLUSTER HEADACHE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CLUSTER HEADACHE MARKET: RESEARCHAI
FIGURE 28. CLUSTER HEADACHE MARKET: RESEARCHSTATISTICS
FIGURE 29. CLUSTER HEADACHE MARKET: RESEARCHCONTACTS
FIGURE 30. CLUSTER HEADACHE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CLUSTER HEADACHE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CLUSTER HEADACHE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ERENUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NSAIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PORTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY STATIONARY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NASAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY DEPARTMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HEADACHE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY GOVERNMENT REIMBURSEMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY OUT-OF-POCKET, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL CLUSTER HEADACHE MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS CLUSTER HEADACHE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES CLUSTER HEADACHE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 221. CANADA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 222. CANADA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 223. CANADA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 224. CANADA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 225. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 226. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 227. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 228. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 229. CANADA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 230. CANADA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 231. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 232. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 233. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 234. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 235. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. CANADA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 238. CANADA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 239. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 240. CANADA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 241. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 242. CANADA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 243. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 244. CANADA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 245. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. CANADA CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. CANADA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. CANADA CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. CANADA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 250. CANADA CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 251. CANADA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 252. CANADA CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 253. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. CANADA CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. CANADA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 256. CANADA CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 257. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 258. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 259. MEXICO CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 260. MEXICO CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 261. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 262. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 263. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 266. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 267. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 268. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 269. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 274. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 275. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 276. MEXICO CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 277. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 278. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 279. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 280. MEXICO CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 281. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 282. MEXICO CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 283. MEXICO CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. MEXICO CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. MEXICO CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 286. MEXICO CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 287. MEXICO CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 288. MEXICO CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 289. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. MEXICO CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 292. MEXICO CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 315. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 316. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 317. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 318. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 319. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 320. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 321. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 322. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 323. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 324. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 325. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 328. BRAZIL CLUSTER HEADACHE MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 331. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 332. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY NONPHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 333. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2018-2024 (USD MILLION)
TABLE 334. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY OXYGEN THERAPY, 2025-2030 (USD MILLION)
TABLE 335. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2024 (USD MILLION)
TABLE 336. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DELIVERY SYSTEMS, 2025-2030 (USD MILLION)
TABLE 337. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2018-2024 (USD MILLION)
TABLE 338. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY PHARMACEUTICAL, 2025-2030 (USD MILLION)
TABLE 339. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 340. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY ANTI-CGRP MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 341. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
TABLE 342. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY TRIPTANS, 2025-2030 (USD MILLION)
TABLE 343. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 344. ARGENTINA CLUSTER HEADACHE MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Cluster Headache market report include:
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • Almirall S.A.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 425.19 Million
Forecasted Market Value ( USD ) by 2030 $ 562.7 Million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cluster Headache - Pipeline Insight, 2025 - Product Image

Cluster Headache - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
COX-2 Selective NSAIDs Market by Route (Injectable, Oral, Topical), Dosage Form (Capsule, Suspension, Tablet), Product, Indication, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

COX-2 Selective NSAIDs Market by Route (Injectable, Oral, Topical), Dosage Form (Capsule, Suspension, Tablet), Product, Indication, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Cancer Pain Management Market by Drug Class (Adjuvant Analgesics, Local Anesthetics, Nsaids), Route Of Administration (Oral, Parenteral, Sublingual), Distribution Channel, End User, Application - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Cancer Pain Management Market by Drug Class (Adjuvant Analgesics, Local Anesthetics, Nsaids), Route Of Administration (Oral, Parenteral, Sublingual), Distribution Channel, End User, Application - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global, United States Global, United States
From
Cluster Headache Syndrome- Pipeline Insight, 2025 - Product Image

Cluster Headache Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Cluster Headache Syndrome Drug Market

Cluster Headache Syndrome (CHS) is a rare neurological disorder characterized by severe, debilitating headaches. It is estimated to affect approximately 0.1% of the population. Treatment for CHS is typically divided into two categories: acute and preventive. Acute treatments are used to provide immediate relief from the pain of a cluster headache attack, while preventive treatments are used to reduce the frequency and severity of attacks. The Cluster Headache Syndrome Drug market is a subset of the Central Nervous System Drugs market. It is composed of pharmaceuticals used to treat CHS, including triptans, ergot alkaloids, and corticosteroids. These drugs are typically administered orally, intranasally, or subcutaneously. The Cluster Headache Syndrome Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.